Excision BioTherapeutics
@ExcisionBio
Developing CRISPR-based therapies intended to cure viral infectious diseases.
You might like
Dr. Ryo Takeuchi, Sr. Director, Genome Editing at Excision, will present on leveraging EBT-101 preclinical and clinical insights for new in vivo multiplex editing programs. Learn more: loom.ly/1IfiuqE
Excision presented data on EBT-107 at the 2024 International HBV Meeting, highlighting its potential to increase Hepatitis B cure rates. Learn more: loom.ly/1IfiuqE
Join us today at 2:30 pm CDT as Dr. Ryo Takeuchi, Senior Director of Genome Editing at Excision, presents on 'Development of Multiplex Gene Editing Therapy for Chronic Hepatitis B' at the 2024 International HBV Meeting. Learn more: loom.ly/1IfiuqE
Today, Excision announced a new publication in Molecular Therapy Methods & Clinical Development on EBT-104 for HSV-1 keratitis treatment. 📍Read the full publication: excision.bio/news/press-rel… #ExcisionBio #MolecularTherapy #HSV #CRISPR #GeneEditing
We're honored to have been awarded one of the 'Fierce 15' Biotech Companies of 2024 by Fierce Biotech. Our unique use of CRISPR/Cas gene editing has recently achieved in vivo proof-of-concept in combating Herpes Virus and Hepatitis B. loom.ly/1IfiuqE #Excision
We're excited to share that Excision BioTherapeutics has been mentioned in a recent article highlighting our Phase 1/2 trial of EBT-101 in HIV and promising preclinical results for herpes and hepatitis B. loom.ly/L8u-X08
Celebrating a successful showcase at #ASGCT2024, Excision Biotherapeutics is proud to have shared our groundbreaking research at the event. We pushed the boundaries of gene therapy, leaving a lasting impact. #Excision #ExcisionBio
Today, Excision BioTherapeutics announced data from our Phase 1/2 Trial of EBT-101 in HIV and In Vivo Efficacy data in Herpes Virus and Hepatitis B. Read our press release: loom.ly/YxPaq_8 #Excision #Excisionbio
TODAY | Join Dr. Rachel Presti for an update on Excision Biotherapeutics’ HIV-1 clinical trial at #ASGCT2024! Discover the transformative potential of our gene editing technologies firsthand. Learn more: loom.ly/aLsEjFo #ExcisionBio #ASGCT #GeneEditing
Mark your calendars for tomorrow, May 10th! Excision Biotherapeutics is gearing up to present our latest advancements in gene editing at #ASGCT2024. Don't miss out on the opportunity to explore the forefront of biotechnology. Visit: loom.ly/aLsEjFo #ExcisionBio #ASGCT
Excision Biotherapeutics is proud to showcase our groundbreaking research at #ASGCT2024! Join us tomorrow, May 9th, as our talented team presents their cutting-edge data. Learn more at: loom.ly/aLsEjFo #ExcisionBio #ASGCT #GeneTherapy
Thank you to Tim Murphy for his recent article highlighting Excision's work in using #CRISPR to combat #HIV. Read his article here: #ExcisionBio #SickleCell #CellGene #GeneEditing
Attending the Oppenheimer 34th Annual Healthcare Life Sciences Conference? Excision will be presenting tomorrow, Tuesday, February 13th at 10:00am ET #ExcisionBio #HIV #LifeSciences #Oppenheimer2024
Check out a recent article from Shawna Williams at @Biospace that highlights Excision's work and how we are setting the foundation for advancements of Excision’s pipeline. Read the article here: loom.ly/KfYZ4kQ
Our team is off to the 7th Annual Cell & Gene Therapy Innovation Leaders Summit 2024 in Barcelona, Spain! We're excited to connect with fellow industry leaders and share how Excision is working towards using #CRISPR technology to combat #HIV. #ExcisionBio #InnovationLeaders
Excision recently sat down with Victoria Johnson from AJMC to discuss our groundbreaking work in the field of CRSIPR and how we seek to suppress #HIV replication using #CRISPR gene editing. Read the article here: loom.ly/qMYoiDs #ExcisionBio HIVResearch
Excision's CEO, Daniel Dornbusch, was delighted to attend this year's #JPM2024 and joined a panel at #BiotechShowcase. It was great meeting Lee Landenberger, @BioWorld reporter. Read his recent article that highlights Excision. Read the article here: loom.ly/9-mncfo
Excited to announce CEO, Daniel Dornbusch's panel on disruptive therapies at #BiotechShowcase2024 during #JPM2024 on Jan 9th, 8 a.m. PT. Thanks to Sara Jane Demy and Demy-Colton team for hosting!
Wishing everyone a Happy New Year filled with joy, success, and exciting breakthroughs! From all of us at the Excision, may the coming year be one of prosperity and remarkable achievements. Here's to a fantastic journey ahead! #HappyNewYear #Excision
Sending warm wishes for a season brimming with love, laughter, and the joy of shared moments. Happy holidays to you and yours! #HappyHolidays #Excision
United States Trends
- 1. Northern Lights 40.2K posts
- 2. #Aurora 8,353 posts
- 3. #DWTS 51.5K posts
- 4. #RHOSLC 6,672 posts
- 5. Justin Edwards 2,251 posts
- 6. Sabonis 6,041 posts
- 7. Louisville 17.7K posts
- 8. Lowe 12.6K posts
- 9. Gonzaga 2,856 posts
- 10. #OlandriaxHarpersBazaar 5,221 posts
- 11. #GoAvsGo 1,531 posts
- 12. Creighton 2,158 posts
- 13. Eubanks N/A
- 14. Andy 60.9K posts
- 15. H-1B 30.8K posts
- 16. JT Toppin N/A
- 17. Oweh 2,084 posts
- 18. Jamal Murray N/A
- 19. Schroder N/A
- 20. Zach Lavine 2,585 posts
You might like
-
The CRISPR Journal
@CRISPRjournal -
David R. Liu
@davidrliu -
Generate:Biomedicines
@generate_biomed -
Scribe Therapeutics
@scribetx -
Nicole M. Gaudelli
@NicoleGaudelli -
Krystal Biotech
@KrystalBiotech -
defeatHIV
@defeatHIV -
TJ Cradick
@NucleaseLab -
Beam Therapeutics
@BeamTx -
Tessera Therapeutics
@TesseraTx -
John Evans
@john_evans3 -
Ardelyx
@ardelyx -
Passage Bio
@Passage_Bio -
RyvuTx
@RyvuTx
Something went wrong.
Something went wrong.